Nora K Lenhard1, James K Sullivan1, Eric L Ross2, Shuang Song1, Robert R Edwards1, David J Hunter3, Tuhina Neogi4, Jeffrey N Katz5, Elena Losina6. 1. Brigham and Women's Hospital, Boston, Massachusetts. 2. Massachusetts General Hospital, Boston, McLean Hospital, Belmont, and Harvard University, Boston, Massachusetts. 3. University of Sydney and Royal North Shore Hospital, Sydney, Australia. 4. Boston University, Boston, Massachusetts. 5. Brigham and Women's Hospital and Harvard University, Boston, Massachusetts. 6. Brigham and Women's Hospital, Harvard University, and Boston University, Boston, Massachusetts.
Abstract
OBJECTIVE: Duloxetine is a treatment approved by the US Food and Drug Administration for both osteoarthritis (OA) pain and depression, though uptake of duloxetine in knee OA management varies. We examined the cost-effectiveness of adding duloxetine to knee OA care in the absence or presence of depression screening. METHODS: We used the Osteoarthritis Policy Model, a validated computer microsimulation of knee OA, to examine the value of duloxetine for patients with knee OA who have moderate pain by comparing 3 strategies: 1) usual care, 2) usual care plus duloxetine for patients who screen positive for depression on the Patient Health Questionnaire 9 (PHQ-9), and 3) usual care plus universal duloxetine. Outcome measures included quality-adjusted life years (QALYs), lifetime direct medical costs, and incremental cost-effectiveness ratios (ICERs), discounted at 3% annually. Model inputs, drawn from the published literature and national databases, included annual cost of duloxetine ($721-937); average pain reduction for duloxetine (17.5 points on the Western Ontario and McMaster Universities Osteoarthritis Index pain scale [0-100]), and likelihood of depression remission with duloxetine (27.4%). We considered 2 willingness-to-pay (WTP) thresholds of $50,000/QALY and $100,000/QALY. We varied parameters related to the PHQ-9 and the cost of duloxetine, efficacy, and toxicities to address uncertainty in model inputs. RESULTS: The screening strategy led to an additional 17 QALYs per 1,000 subjects and increased costs by $289/subject (ICER = $17,000/QALY). Universal duloxetine led to an additional 31 QALYs per 1,000 subjects and $1,205 per subject (ICER = $39,300/QALY). Under the majority of sensitivity analyses, universal duloxetine was cost-effective at the $100,000/QALY threshold. CONCLUSION: The addition of duloxetine to usual care for knee OA patients with moderate pain, regardless of depressive symptoms, is cost-effective at frequently used WTP thresholds.
OBJECTIVE: Duloxetine is a treatment approved by the US Food and Drug Administration for both osteoarthritis (OA) pain and depression, though uptake of duloxetine in knee OA management varies. We examined the cost-effectiveness of adding duloxetine to knee OA care in the absence or presence of depression screening. METHODS: We used the Osteoarthritis Policy Model, a validated computer microsimulation of knee OA, to examine the value of duloxetine for patients with knee OA who have moderate pain by comparing 3 strategies: 1) usual care, 2) usual care plus duloxetine for patients who screen positive for depression on the Patient Health Questionnaire 9 (PHQ-9), and 3) usual care plus universal duloxetine. Outcome measures included quality-adjusted life years (QALYs), lifetime direct medical costs, and incremental cost-effectiveness ratios (ICERs), discounted at 3% annually. Model inputs, drawn from the published literature and national databases, included annual cost of duloxetine ($721-937); average pain reduction for duloxetine (17.5 points on the Western Ontario and McMaster Universities Osteoarthritis Index pain scale [0-100]), and likelihood of depression remission with duloxetine (27.4%). We considered 2 willingness-to-pay (WTP) thresholds of $50,000/QALY and $100,000/QALY. We varied parameters related to the PHQ-9 and the cost of duloxetine, efficacy, and toxicities to address uncertainty in model inputs. RESULTS: The screening strategy led to an additional 17 QALYs per 1,000 subjects and increased costs by $289/subject (ICER = $17,000/QALY). Universal duloxetine led to an additional 31 QALYs per 1,000 subjects and $1,205 per subject (ICER = $39,300/QALY). Under the majority of sensitivity analyses, universal duloxetine was cost-effective at the $100,000/QALY threshold. CONCLUSION: The addition of duloxetine to usual care for knee OA patients with moderate pain, regardless of depressive symptoms, is cost-effective at frequently used WTP thresholds.
Authors: John Axford; Alexander Butt; Christine Heron; John Hammond; John Morgan; Azita Alavi; Jim Bolton; Martin Bland Journal: Clin Rheumatol Date: 2010-08-19 Impact factor: 2.980
Authors: Elena Losina; Jamie E Collins; John Wright; Meghan E Daigle; Laurel A Donnell-Fink; Doris Strnad; Ilana M Usiskin; Heidi Y Yang; Vladislav Lerner; Jeffrey N Katz Journal: Arthritis Care Res (Hoboken) Date: 2016-07-28 Impact factor: 4.794
Authors: Elizabeth A Wright; Jeffrey N Katz; Stanley Abrams; Daniel H Solomon; Elena Losina Journal: Arthritis Care Res (Hoboken) Date: 2014-10 Impact factor: 4.794
Authors: Elena Losina; Rochelle P Walensky; William M Reichmann; Holly L Holt; Hanna Gerlovin; Daniel H Solomon; Joanne M Jordan; David J Hunter; Lisa G Suter; Alexander M Weinstein; A David Paltiel; Jeffrey N Katz Journal: Ann Intern Med Date: 2011-02-15 Impact factor: 25.391
Authors: Ronald C Wielage; Megha Bansal; J Scott Andrews; Robert W Klein; Michael Happich Journal: Appl Health Econ Health Policy Date: 2013-06 Impact factor: 2.561
Authors: Joel Raskin; Curtis G Wiltse; Alan Siegal; Javaid Sheikh; Jimmy Xu; James J Dinkel; Benjamin T Rotz; Richard C Mohs Journal: Am J Psychiatry Date: 2007-06 Impact factor: 18.112
Authors: Gillian D Sanders; Peter J Neumann; Anirban Basu; Dan W Brock; David Feeny; Murray Krahn; Karen M Kuntz; David O Meltzer; Douglas K Owens; Lisa A Prosser; Joshua A Salomon; Mark J Sculpher; Thomas A Trikalinos; Louise B Russell; Joanna E Siegel; Theodore G Ganiats Journal: JAMA Date: 2016-09-13 Impact factor: 56.272